Edwards Lifesciences Corporation $EW Shares Purchased by AIA Group Ltd

AIA Group Ltd increased its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 7.9% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 137,043 shares of the medical research company’s stock after purchasing an additional 10,083 shares during the period. AIA Group Ltd’s holdings in Edwards Lifesciences were worth $10,974,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after acquiring an additional 4,108,270 shares in the last quarter. Viking Global Investors LP acquired a new position in Edwards Lifesciences during the 3rd quarter worth $238,688,000. Marshall Wace LLP increased its stake in shares of Edwards Lifesciences by 66.1% during the fourth quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after buying an additional 2,359,128 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Edwards Lifesciences by 221.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,060,891 shares of the medical research company’s stock valued at $167,468,000 after purchasing an additional 1,419,022 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This represents a 19.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $91.70, for a total value of $56,762.30. Following the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,671,117.80. The trade was a 1.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 45,577 shares of company stock worth $3,855,527. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW opened at $85.72 on Friday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The firm has a market cap of $49.36 billion, a PE ratio of 45.60, a price-to-earnings-growth ratio of 2.15 and a beta of 0.86. The company’s 50 day simple moving average is $87.34 and its 200-day simple moving average is $83.94. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on EW shares. Mizuho raised their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday. BTIG Research increased their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. TD Cowen reiterated a “buy” rating and set a $104.00 price target (up from $97.00) on shares of Edwards Lifesciences in a research note on Tuesday, June 2nd. Barclays reissued an “overweight” rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Finally, Robert W. Baird upped their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $98.95.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.